All about improving therapeutic outcomes to TMS and neurofeedback using replicated and clinically actionable biomarkers.
Look forward presenting a keynote and workshop at ISNR conference in Las Vegas in August. Will focus on Heart-Brain Coupling and QEEG-based Stratified Psychiatry in ADHD and Depression.
See you there?
web.cvent.com/event/cdfcfc...
Look forward to presenting @UCLA on alpha frequency and heart-brain coupling as biomarkers for personalized TMS.
But why use 8mg+8mg in prospective Ph3 study (instead of 8+12mg)? Use of 4mg as a control also sounds risky, might lack 'dose-response' effects.
Even taking more specific TRD treatments e.g. SAINT (50% remission); our own TMS+psychotherapy data (56% remission), a 76% remission rate is high.
SAINT Replication: onlinelibrary.wiley.com/doi/10.1002/...
TMS+Psychotherapy: www.brainstimjrnl.com/article/S193...
To put this into perspective, here all reponse/remission rates for current treatments in MDD and TRD from largest open-label trials incl. STAR*D, iSPOT-D, Blumberger et al. etc. Normally 30-40% remission rate in TRD.
See here for refs: www.nature.com/articles/s44...